Toward Greater Transparency at the FDA—Now Is the Time to Act

This Viewpoint considers the US Food and Drug Administration’s track record for transparency and urges the agency to fortify transparency efforts.

Corresponding Author: Peter G. Lurie, MD, MPH, Center for Science in the Public Interest, 1250 I St NW, Ste 500, Washington, DC 20005 (plurie@cspi.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.